# Optimize Formulation of VSA Adjuvant

> **NIH NIH N43** · ADJUVAX LLC · 2022 · $600,000

## Abstract

The contract supports the development of a saponin as a vaccine adjuvant.  The adjuvant development activities are being conducted within the context of vaccines to protect against SARS-CoV-2 and pneumococcal infection.

## Key facts

- **NIH application ID:** 10678489
- **Project number:** 75N93022C00033-0-9999-1
- **Recipient organization:** ADJUVAX LLC
- **Principal Investigator:** DAVID CLEMENTS
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $600,000
- **Award type:** —
- **Project period:** 2022-07-05 → 2024-07-05

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10678489

## Citation

> US National Institutes of Health, RePORTER application 10678489, Optimize Formulation of VSA Adjuvant (75N93022C00033-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10678489. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*